Exagen Inc (XGN) Q1 2026 Earnings Call Transcript

Why It Matters

The higher Medicare reimbursement and expanded payer coverage could accelerate Exagen’s revenue growth and improve profitability in a market hungry for precision‑medicine diagnostics.

Key Takeaways

• Record 2,175 providers and 761 adopters in Q1
• Medicare PLA code raises Lupus test price to $1,085
• Q1 revenue $10.4M, gross margin fell to 44%
• Guidance lifted to $53‑55M for full year 2022
• AVISE RADR aims to predict rheumatoid arthritis drug response

Pulse Analysis

Exagen’s Q1 performance underscores the growing demand for molecular diagnostics in rheumatology, especially as clinicians seek tools that reduce diagnostic uncertainty. The company’s AVISE CTD platform, anchored by its proprietary CB‑CAP technology, delivered a record volume of tests despite pandemic‑related disruptions. By securing a Medicare PLA code that more than triples reimbursement for AVISE Lupus, Exagen not only improves its average selling price but also sets a precedent for future payer negotiations, potentially unlocking higher margins across its test portfolio.

The financial picture reflects both opportunity and growing pains. While revenue rose modestly, gross margins contracted to 44% due to higher per‑test costs and a shift in payer mix. Operating expenses surged as Exagen invests heavily in R&D, AI‑driven AVISE RADR development, and expanded sales infrastructure across 63 territories. Nonetheless, a robust cash position of nearly $90 million provides runway for continued innovation and market penetration, supporting the company’s raised guidance of $53‑55 million for 2022.

Looking ahead, Exagen’s pipeline positions it to capitalize on the broader precision‑medicine trend. AVISE RADR, designed to predict therapeutic response in rheumatoid arthritis, addresses a $18 billion spend gap identified by analysts. Early market research shows 80% of rheumatologists favor personalized treatment pathways, suggesting strong adoption potential. Combined with the new PLA code and expanding payer contracts, Exagen is poised to strengthen its foothold in the high‑value diagnostics space, offering investors a compelling growth narrative anchored in scientific differentiation and strategic reimbursement wins.